Alosetron: case study in regulatory capture, or victory for patients’ rights? – (09-19-02)



Alosetron: case study in regulatory capture, or victory for patients’ rights?

This article brings to light the scary concept that the FDA is funded strongly by the pharmaceutical companies they are supposed to regulate. Does anyone get a little nervous about this association besides me?

bmj.com Moynihan 325 (7364): 592

Read entire article here

James Bogash

For more than a decade, Dr. Bogash has stayed current with the medical literature as it relates to physiology, disease prevention and disease management. He uses his knowledge to educate patients, the community and cyberspace on the best way to avoid and / or manage chronic diseases using lifestyle and targeted supplementation.







Email:



Posted on
Category: Drug Research
Disclosure of Material Connection: Some of the links in the post above are “affiliate links.” This means if you click on the link and purchase the item, I will receive an affiliate commission. Regardless, I only recommend products or services I use personally and believe will add value to my readers. I am disclosing this in accordance with the Federal Trade Commission’s 16 CFR, Part 255: “Guides Concerning the Use of Endorsements and Testimonials in Advertising.”